Bristol-Myers Squibb (BMY) has seen some drastic fluctuations in the market, despite recent upward momentum. The company has just settled cases pertaining to their psoriasis and MS drugs for a substantial $239 million. However, BMY has also beat earnings estimates and reported robust Q3 figures. This is thanks largely to strong sales of Opdivo, their cancer treatment drug, and its extensive investment in portfolio growth. Despite witnessing a recent one-off loss of $6.6 billion, the stock has performed well. A significant move by the company to expand their cell therapy portfolio with a $1.5 billion Orbital Therapeutics deal could positively affect future performance. Some note-worthy updates include an upgrade in BMY's stock rating by Wall Street Zen, a consensus rating of 'Hold' by analysts and rising global Breyanzi sales. There're reports of a decline expected in BMY's earnings and issues with Cobenfy, BMY's schizophrenia drug, underperforming in sales. Attentions are also drawn to a $3.18 million lobbying disclosure and the pricing of €5 billion of senior unsecured notes.
Bristol-Myers Squibb BMY News Analytics from Wed, 14 May 2025 07:00:00 GMT to Sat, 08 Nov 2025 14:10:57 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -3
